Peak Bio, Inc. Announces Up-listing to OTCQB Market

临床1期抗体药物偶联物
Peak Bio, Inc. Announces Up-listing to OTCQB Market
Pleasanton, CA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTC PK: PKBO), is a clinical-stage biopharmaceutical company focused on developing and commercializing the next-generation of innovative therapeutics that aim to improve and address significant unmet medical need for patients with inflammatory, rare-specialty diseases and
cancer
. The Company today is pleased to announce its successful up-listing from the OTC Pink Market to the OTCQB® Venture Market (the"OTCQB") effective for trading August 31, 2023 at the open. Peak Bio will continue to trade under the ticker symbol "PKBO".
The Company believes that the move to the OTCQB will provide enhanced investor benefits including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance requirements. The OTCQB is considered by the Securities and Exchange Commission (SEC) as an "established public market" for determining the public market price when registering securities for resale with the SEC. Because the OTCQB dramatically increases transparency, reporting standards, management certification and compliance requirements, we believe the Company will benefit from increased broker-dealer participation. Historically, companies that have made the move up to the OTCQB® tier have experienced increased investor awareness, greater liquidity and
visibility of their common stock.
Stephen LaMond, PharmD, MBA, Peak Bio, Inc. Interim CEO and COO, commented, "We are pleased to announce Peak Bio has achieved another milestone with our move to the OTCQB® Venture Market from the OTC Pink Market. We believe this will increase opportunities for more exposure to our scientific and investor community of our continued mission to bring advanced
cancer
and rare/orphan disease therapies to market. In addition, we expect the move to provide greater liquidity and visibility for our common stock and additional optionality on OTCQB or other exchanges in the future.”
About OTC Markets Group and the OTCQB® Venture Market
The OTCQB, operated by OTC Markets Group, Inc.,( https://www.otcmarkets.com) is a premier market designed for developing and entrepreneurial companies in the United States and abroad committed to providing investors high quality trading and improved market visibility to enhance trading liquidity. To be eligible for trading on the OTCQB, companies must be current in their financial reporting with the Securities and Exchange Commission (the "SEC"), pass a minimum bid price test, maintain audited financials through a PCAOB registered firm, an undergo company verification and management certification on an annual basis. The OTCQB is operated by the OTC Markets Group (https://www.otcmarkets.com) and recognized by the Securities and Exchange Commission ("SEC") as an established public market providing data that investors need to analyze, value and trade securities. Being part of the OTC Markets Group will assist in diversifying Peak Bio’s shareholder base worldwide.
About Peak Bio, Inc.
Peak Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases. Peak Bio’s lead product candidate, PHP-303, is a 5th generation, small molecule, neutrophil elastase inhibitor
neutrophil elastase
inhibitor currently awaiting initiation of a Phase II clinical study in the
genetic orphan disease
called
Alpha1 anti-trypsin deficiency disorder (AATD)
. Peak Bio has successfully completed two Phase 1 clinical studies in human subjects: a single ascending dose trial (SAD) and a multiple ascending dose trial (MAD). The SAD and MAD PHP-303 clinical studies demonstrated a favorable safety profile, and a dose was established for Peak Bio’s upcoming clinical trials. Peak Bio’s
cancer
platform consists of novel payloads/toxins in conjunction an antibody-drug conjugate (ADC) platform that seeks to address a growing unmet need in
cancer
care. Peak Bio’s current ADC approach has a dual mechanism of action that seeks to combine conventional and direct targeting of
cancer
cells with toxins while also engaging the immune system with the added potential to enhance
cancer
cell killing. The Peak Bio payload seeks to stimulate the immune system by leaving behind immune memory cells that continue to kill
cancer
cells following the initial therapeutic intervention even in the absence of further ADC treatments. The potential for immune reengagement when the
cancer
reoccurs could be an exciting and important advancement in
cancer
care with this dual mechanistic approach to
cancer
therapeutics. Peak Bio’s lead payload appears to be a poor substrate for
multi-drug resistance (MDR) transporters
which is a growing concern in the ADC field.
For additional information, please visit our corporate website at: www.Peak-Bio.com
Safe Harbor Statement Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Forward-looking statements generally can be identified by terms such as “aims,” “anticipates,” “believes,” “contemplates,” “continues,” “could,” “estimates,” “expects,” “goal,” “intends,” “may,” “on track,” “opportunity,” “plans,” “poised for,” “possible,” “potential,” “predicts,” “projects,” “promises to be,” “seeks,” “should,” “target,” “will,” “would” or similar expressions and the negatives of those terms. Although we believe that our plans, intentions, expectations, strategies, and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; preclinical testing or early clinical results may not be predictive of the results or success of ongoing or later preclinical or clinical studies; identification, development and testing of the company’s product candidates and new platforms may take longer and/or cost more than planned, or our clinical studies may not be initiated or completed on schedule; risks inherent in drug development in general; difficulties enrolling patients in our clinical trials; failure to realize any value of our product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risks associated with the impact of the COVID-19 pandemic; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission (“SEC”), including our most recently filed Registration Statement on Form S-1 filed with the SEC and our most recently filed Annual Report on Form 10-K filed with the SEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.
Contact:
Stephen LaMond, PharmD, MBA
Interim CEO and COO
Peak Bio, Inc.
steve.lamond@peak-bio.com


更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
适应症
肿瘤,罕见病,α1-抗胰蛋白酶缺乏症
靶点
ELA2,Transporters
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。